CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review
Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.
How this was made
The 30-second read
Why it matters
The trial success could accelerate the timeline to regulatory filing and boost valuation.
Market read
New positive data for a small‑cap biotech, likely to drive short‑term price movement.
What to watch
Cash runway of $198.5 M may limit long‑term upside if approval is delayed.
Background
Capricor reported no revenue and a widened Q3 loss, but highlighted a significant clinical milestone for its lead candidate Deramiocel.
Ticker impact
Capricor Therapeutics reaffirmed confidence in its Deramiocel candidate after HOPE-3 met its primary endpoint, a fresh clinical‑trial result.
upward pressure as investors price in potential FDA approval
The primary endpoint success is new material information for a biotech, and the stock already rallied after‑hours.
Market effects
May lift sentiment for other gene‑therapy and rare‑disease biotech stocks.
Limited to US biotech sector.
Modest; primarily affects investors tracking clinical‑trial pipelines.
Counterpoint
If the FDA requires additional data, the rally could reverse.
Key entities
- companyCapricor Therapeutics
Biotech developing Deramiocel for muscular dystrophy.
- clinical_trialHOPE-3
Phase 2b study showing primary endpoint met.
